Skip to main content
Sign In

Welcome to the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine on the Anschutz Medical Campus in Aurora, Colorado.

Barbara Davis Center Banner Image
 

Phase II trial of hOKT3g1(Ala-Ala), Teplizumab

for treatment of patients with recent onset Type 1 diabetes mellitus (Delay Study)


 

Principal Investigator: Peter Gottlieb MD, COMIRB # : 07-0927

The “Delay” Research Study is looking for people recently diagnosed with type 1 diabetes within the past 4-12 months. 

This research study will use the medication hOKT3g1(Ala-Ala), also called Teplizumab, to see if we can change the immune system to maintain the body’s ability to produce some insulin.

Why should you consider this study?

  • When you are first diagnosed with Type 1 Diabetes you still make some insulin
  • Over time, your body will lose the ability to make this insulin
  • This study will use a medication to try to keep your body making its own insulin
  • This medication has been shown to extend the honeymoon period in new onset subjects
  • While your body continues to make its own insulin, your diabetes will be easier to control
  • Continued production of some insulin can decrease the risk for long term complications of type 1 diabetes

Who can sign up for this study?

  • People recently diagnosed with Type 1 Diabetes within the past 4 – 12 months
  • 8 years old – 30 years old

What will happen in this study?

  • You will be assessed for general health and diabetes care
  • If you qualify, you will receive treatment with study medication, or fake medication, once per day for 14 consecutive days
  • You will be monitored for up to 2 additional years to look at your overall diabetes health

Who should I call with questions or to schedule an appointment?

Whitney Kastelic: 303-724-7502 or Whitney.Kastelic@ucdenver.edu
Lisa Meyers:      303-724-6893 or Lisa.Meyers@ucdenver.edu

http://clinicaltrials.gov/ct2/show/NCT00378508